---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-028601"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T00:33:54.942388+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Alnylam Q1 net product revs $1.04B (+121%); GAAP EPS $1.51 vs -$0.14; reaffirms FY26 guidance

## Summary
- Global net product revenues $1,036M, up 121% YoY; total TTR revenues $910M (+153%).
- GAAP net income $206M vs loss $18M; GAAP diluted EPS $1.51; non-GAAP EPS $1.99.
- Reiterates FY26 combined net product revenue guidance of $4.9B-$5.3B.
- AMVUTTRA (vutrisiran) net product revenues $890M; TRITON-CM expanded to ~1,750 patients.
- Initiated Phase 1 obesity trial (ALN-2232) and new collaborations with Viz.ai, AHA, Tenaya, Helix.

## SEC filing metadata
- accession: 0001628280-26-028601
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000162828026028601/0001628280-26-028601-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000162828026028601/alny-20260430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-028601
- JSON: https://secwatch.observer/filing/0001628280-26-028601.json
- Plain text: https://secwatch.observer/filing/0001628280-26-028601.txt

## Key facts
- Earnings Releases
  ALNYLAM PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2026 results: revenue $1,036 Million. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2026
  - Revenue: $1,036 Million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period Progress − Achieved First Quarter 2026 Global Net Product Revenues of $1,036 Million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000162828026028601/0001628280-26-028601-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.